Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
AssigneeMorehouse School of Medicine
InventorsGale W. Newman, James W. Lillard, Jr., Chamberlain Obialo
Life of this patent
Estimating the term…
Abstract
The present application relates to methods of treating HIV-associated nephropathy (HIVAN) and/or focal segmental glomerulosclerosis (FSGS) using endothelin-1 (ET-1) antagonists. The application further relates to a composition for the treatment of HIVAN and/or FSGS. A kit for detecting the presence of ET-1 or ET-1-associated biomarker in a biological sample is also disclosed.
Claims6
A method of treating IgA nephropathy directly linked to increased levels of ET-1 compared to ET-1 levels in those without IgA nephropathy, in a mammalian subject in need thereof and diagnosed at a qualified medical center as having said IgA nephropathy, by administering an effective amount of a pharmaceutical composition comprising:
- (1) an active ingredient consisting of an ET-1 antagonist;
- and
- (2) a pharmaceutically acceptable carrier,
- wherein the active ingredient is the only active ingredient in the pharmaceutical composition, wherein the subject has an increased level of ET-1 compared to a control subject, and wherein the ET-1 antagonist is selected from the group consisting of sitaxentan, ambrisentan, atrasentan, BQ-123, bosentan and tezosentan.
A method of monitoring the effectiveness of a treatment for IgA nephropathy directly linked to increased levels of ET-1 compared to ET-1 levels in those without IgA nephropathy, in a mammalian subject in need thereof and diagnosed at a qualified medical center as having said IgA nephropathy, comprising the steps of:
- (a) administering to a subject with IgA nephropathy directly linked to increased levels of ET-1 compared to ET-1 levels in those without IgA nephropathy, in a mammalian subject in need thereof and diagnosed at a qualified medical center as having said IgA nephropathy, a pharmaceutical composition comprising:
- (1) an active ingredient consisting of an ET-1 antagonist;
- and
- (2) a pharmaceutically acceptable carrier,
- wherein the active ingredient is the only active ingredient in the pharmaceutical composition and wherein the ET-1 antagonist is selected from the group consisting of sitaxentan, ambrisentan, atrasentan, BQ-123, bosentan and tezosentan;
- (b) performing a first measurement of an ET-1-associated biomarker in a first biological sample from the subject, wherein the first biological sample is harvested prior to the initiation of the treatment in step (a);
- (c) comparing the first measurement of an ET-1-associated biomarker to a control subject;
- (d) performing a second measurement of the ET-1-associated biomarker in a second biological sample from the subject, wherein the second biological sample is harvested after the initiation of the treatment in step (a);
- and
- (e) determining the effectiveness of treatment for IgA nephropathy directly linked to increased levels of ET-1, based on the results from step (d) in comparison to step (b) as to the level of ET-1 as the ET-1-associated biomarker and adjusting the amount of ET-1 inhibitor administration based thereon;
- and separately determining the effect of treatment for IgA nephropathy directly linked to increased levels of ET-1, based on the results from step (d) in comparison to step (b) as to the level of any one or more ET-1-associated biomarkers selected from the group consisting of preproendothelin (ppET-1), proendothelin-1 (pET-1), BIG ET-1, endothelin converting enzyme (ECE), cystatin C, creatinine and albumin-creatinine ratio (ACR), and adjusting the amount of ET-1 inhibitor administration based thereon.
Dependencies are inferred from the claim text.